Promising clinical results from our first patient show tumor reduction at two months! These are encouraging early findings from our Deltacel-01 Phase 1 clinical trial treating stage 4 metastatic non-small cell lung cancer (NSCLC) at Beverly Hills Cancer Center for patients who have limited treatment options. #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eUCpnjQT
Kiromic Biopharma, Inc.’s Post
More Relevant Posts
-
Managing Partner and Client Services Director @ infill and Project Director @ memo inOncology / memo inHaematology
A new article on memo inOncology! Small-cell lung cancer: insights and new treatment options centering around DLL3 Visit memoinoncology.com for more updates on oncology and haematology! #esmo2023 #oncology #DLL3 #lungcancer #ESMO #ASCO #medicaleducation
New from memo! 𝐒𝐦𝐚𝐥𝐥-𝐜𝐞𝐥𝐥 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫: 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐧𝐞𝐰 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐭𝐢𝐨𝐧𝐬 𝐜𝐞𝐧𝐭𝐞𝐫𝐢𝐧𝐠 𝐚𝐫𝐨𝐮𝐧𝐝 𝐃𝐋𝐋𝟑 A new article covering the latest in lung cancer research from ESMO 2023 is now available on memo inOncology! Linked below, check out the latest results in: • DLL3 as target with prognostic and predictive value • DeLLphi-301: tarlatamab at two doses • Recruitment halt in TREASURE #esmo2023 #oncology #DLL3 #lungcancer
Small-cell lung cancer: insights and new treatment options centering around DLL3
https://memoinoncology.com
-
New Blog Alert! Want to learn more about the current treatment options for RET-positive lung cancer? Discover how these current therapies are transforming the landscape of lung cancer treatment and offering new hope. Read more at the link to stay informed and empowered: https://lnkd.in/gHE9MDxw #HappyLungsProject #LungCancerAwareness #RETPositive #TargetedTherapies #CancerTreatment #lungcancer
Current Treatment Options for RET Lung Cancer - The Happy Lungs Project
https://happylungsproject.org
-
The dual primary end points of the phase 3 KEYLYNK-006 trial, which was exploring first-line pembrolizumab plus olaparib in patients with metastatic nonsquamous non–small cell lung cancer, were not met. https://lnkd.in/ej36A9u3 #NSCLC #cancer #Oncology
Primary End Points Not Met With Pembrolizumab/Olaparib in NSCLC Trial
cancernetwork.com
-
WATCH: Expert oncologists review updates in the treatment of small cell lung cancer that were presented at key conferences in 2022 and discuss data in the context the current treatment landscape. #oncology #lungcancer https://lnkd.in/eBifGffb
Novel and Emerging Frontline Treatment Strategies in SCLC
onclive.com
-
Early stage non–small cell lung cancer has been evolving in real time over the past few years, with multiple key trials of neoadjuvant &/or adjuvant therapy trials incorporating targeted therapy or immunotherapy; this review summarizes data & recs for current clinical practice. https://ja.ma/3RY8Cbv
Rapid Advances in Resectable Non–Small Cell Lung Cancer
jamanetwork.com
-
Combining pembrolizumab with lenvatinib did not improve progression-free or overall survival compared with standard-of-care options in select patients with metastatic non–small cell lung cancer in 2 phase 3 studies. https://lnkd.in/eiZdxVyA #NSCLC #cancer #oncology
Pembrolizumab Combos Miss Survival End Points in Metastatic NSCLC
cancernetwork.com
-
CEO and Managing Director of Lungscreen Foundation | Industrial Lung Screening | Lung Cancer Screening | Lung Nodule Management | Radiology | Thoracic Imaging | Helping Save Lives by Detecting Lung Disease Early
New lung cancer drugs could revolutionise non small cell lung cancer treatment, reducing the need for chemotherapy. These treatments make lung screening and keeping up with research trends more important than ever - when lung cancer is screened and treated by lung cancer specialists with access to these new findings. Patients can get a more personalised treatment, increasing the chances of recovery. #lungcancer #research #lungscreening
New treatment options offer hope for patients with non-small cell lung cancer
news-medical.net
-
We’re making significant progress in the fight against #lungcancer. Today at #ASCO24, we shared important results from our Phase 3 clinical trial evaluating treatments for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). After five years of median follow-up, one of our treatments showed unprecedented progression-free survival, with 60% of patients alive without disease worsening. Lung cancer is the #1 cause of cancer-related death around the world. We have spent years at Pfizer working on developing potential solutions that can help people with cancer live better and longer lives. These results represent Pfizer’s commitment to advancing outcomes for patients. https://lnkd.in/exjYrybQ
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
pfizer.com
-
Early stage non–small cell lung cancer has been evolving in real time over the past few years, with multiple key trials of neoadjuvant &/or adjuvant therapy trials incorporating targeted therapy or immunotherapy; this review summarizes data & recs for current clinical practice. https://ja.ma/49FrJNT
Rapid Advances in Resectable Non–Small Cell Lung Cancer
jamanetwork.com
-
Expert: PALOMA-3 Trial Results, Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment: The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients. #finance #pharmacy #lifesciences
Expert: PALOMA-3 Trial Results, Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
pharmacytimes.com
CEO and Executive Director at Kiromic Biopharma, Inc.
5moAmazing result from an amazing Team! Our thoughts and hearts are for this first patient and for all many other patients who are waiting for our help: I guarantee we’ll continue to pursue our mission to help mankind with incredible passion and motivation!